Tempus AI shares are up about 4.6% in Wednesday trading (April 1, 2026) with no clearly identifiable same-day company press release or major SEC filing driving the move. Instead, traders appear to be fading recent negative sentiment tied to insider-transaction headlines and rotating back into the stock on the view that the fundamental narrative remains intact following the company’s Q4/full-year 2025 results and 2026 revenue guidance.

Over the past week, TEM has been in the cross-currents of (1) quarterly-results digestion and (2) insider-transaction headlines that can pressure high-growth healthcare/AI names. Market chatter has also highlighted retail sentiment swings and incremental institutional/ETF activity, which can amplify day-to-day volatility even without a new fundamental update. (investors.tempus.com)

In fast-moving growth stocks, a rebound day often comes from positioning rather than new information—especially after headline-driven selling. If selling pressure eases and incremental buyers step in, TEM can lift even on a quiet news tape; options hedging and short covering can further accelerate a move. Investors will be watching for the next concrete catalyst—new customer wins, updated guidance, or additional clinical/AI product milestones—to confirm whether the bounce has follow-through.